Study of ADH-1 Given Intravenously to Patients With Solid Tumors
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer
progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study
will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a
protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that
subjects can tolerate.